» Articles » PMID: 26851259

Increased Susceptibility of Cftr-/- Mice to LPS-induced Lung Remodeling

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is caused by homozygous mutations of the CF transmembrane conductance regulator (CFTR) Cl(-) channel, which result in chronic pulmonary infection and inflammation, the major cause of morbidity and mortality. Although these processes are clearly related to each other, each is likely to contribute to the pathology differently. Understanding the contribution of each of these processes to the overall pathology has been difficult, because they are usually so intimately connected. Various CF mouse models have demonstrated abnormal immune responses compared with wild-type (WT) littermates when challenged with live bacteria or bacterial products acutely. However, these studies have not investigated the consequences of persistent inflammation on lung tissue in CF mice, which may better model the lung pathology in patients. We characterized the lung pathology and immune response of Cftr(-/-) (CF) and Cftr(+/+) (WT) mice to chronic administration of Pseudomonas aeruginosa lipopolysaccharide (LPS). We show that, after long-term repeated LPS exposure, CF mice develop an abnormal and persistent immune response, which is associated with more robust structural changes in the lung than those observed in WT mice. Although CF mice and their WT littermates develop lung pathology after chronic exposure to LPS, the inflammation and damage resolve in WT mice. However, CF mice do not recover efficiently, and, as a consequence of their chronic inflammation, CF mice are more susceptible to morphological changes and lung remodeling. This study shows that chronic inflammation alone contributes significantly to aspects of CF lung pathology.

Citing Articles

Antimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.

Murphy R, Pizzato J, Cuthbertson L, Sabnis A, Edwards A, Nolan L NPJ Antimicrob Resist. 2025; 2(1):4.

PMID: 39843948 PMC: 11702655. DOI: 10.1038/s44259-024-00022-x.


Ezrin drives adaptation of monocytes to the inflamed lung microenvironment.

Gudneppanavar R, Di Pietro C, H Oz H, Zhang P, Cheng E, Huang P Cell Death Dis. 2024; 15(11):864.

PMID: 39613751 PMC: 11607083. DOI: 10.1038/s41419-024-07255-8.


Effects of CFTR-ENaC on spinal cord edema after spinal cord injury.

Shen G, Zhang Y, Cheng X, Li D, Ding Z, Tian J Open Med (Wars). 2024; 19(1):20241082.

PMID: 39588386 PMC: 11587918. DOI: 10.1515/med-2024-1082.


Epithelial-Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?.

Mottais A, Riberi L, Falco A, Soccal S, Gohy S, De Rose V Int J Mol Sci. 2023; 24(15).

PMID: 37569787 PMC: 10418908. DOI: 10.3390/ijms241512412.


CFTR dysfunction in smooth muscle drives TGFβ dependent airway hyperreactivity.

Kramer E, Hudock K, Davidson C, Clancy J Respir Res. 2023; 24(1):198.

PMID: 37568151 PMC: 10416378. DOI: 10.1186/s12931-023-02495-2.


References
1.
van Heeckeren A, Tscheikuna J, Walenga R, Konstan M, DAVIS P, Erokwu B . Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med. 2000; 161(1):271-9. DOI: 10.1164/ajrccm.161.1.9903019. View

2.
Soltys J, Bonfield T, Chmiel J, Berger M . Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol. 2002; 168(4):1903-10. DOI: 10.4049/jimmunol.168.4.1903. View

3.
Hilliard J, Konstan M, Davis P . Inflammatory mediators in CF patients. Methods Mol Med. 2002; 70:409-31. DOI: 10.1385/1-59259-187-6:409. View

4.
Brass D, Savov J, Gavett S, Haykal-Coates N, Schwartz D . Subchronic endotoxin inhalation causes persistent airway disease. Am J Physiol Lung Cell Mol Physiol. 2003; 285(3):L755-61. DOI: 10.1152/ajplung.00001.2003. View

5.
Chmiel J, Davis P . State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respir Res. 2003; 4:8. PMC: 203156. DOI: 10.1186/1465-9921-4-8. View